Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax
Frontiers in Oncology · 05.06.2026 · 16
DOI: 10.3389/fonc.2026.1828240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 05.06.2026. Verfasst von Fangli Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
The With-No-Lysine (WNK) kinase family plays critical roles in cellular signaling, yet its significance in acute myeloid leukemia (AML) remains unclear.
Methods
We analyzed public databases and primary patient samples for WNK family expression. CRISPR dependency scores were used to assess gene essentiality. The effects of pharmacological WNK1 inhibition (using WNK463 and WNK11) were evaluated on AML cell lines, primary blasts, and mouse xenograft models. Apoptosis was assessed via pro-apoptotic protein expression (Bim, Puma). Transcriptomic analysis identified downstream pathways, and combination studies with venetoclax were performed in vitro .
Results
WNK1, but not other WNK family members, was highly expressed in AML, particularly in adverse subtypes such as FLT3-ITD mutated AML. CRISPR screening confirmed WNK1 as essential for AML cell survival. Pharmacological inhibition of WNK1 suppressed proliferation of AML cells and primary blasts, induced apoptosis through upregulation of Bim and Puma, and impeded tumor growth in xenograft models without significant toxicity. Transcriptomic analysis revealed that WNK1 inhibition downregulated DNA replication pathway genes (MCM5, CHAF1B, GINS2), whose high expression correlates with poor prognosis. Elevated WNK1 expression was associated with resistance to venetoclax. Combining WNK463 with venetoclax produced synergistic anti-leukemic effects in vitro , accompanied by enhanced Bim upregulation.
Discussion
This study identifies WNK1 as a key oncogenic driver in AML and establishes WNK1 inhibition as a promising therapeutic strategy that not only suppresses AML progression but also sensitizes leukemia cells to venetoclax. These findings provide a rationale for novel combination regimens to overcome drug resistance in AML.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, F., Wang, Y., Fu, Z., Chang, L., Jiang, X., Zhang, Z., Li, C., Liu, L., & Yang, L. (2026). Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1828240
Vancouver
Chen F, Wang Y, Fu Z, Chang L, Jiang X, Zhang Z, et al. Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1828240
BibTeX
@article{Chen2026,
author = {Chen, Fangli and Wang, Yuanqin and Fu, Zhen and Chang, Li and Jiang, Xuewei and Zhang, Zhizhi and Li, Chongyang and Liu, Ligen and Yang, Li},
title = {Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1828240}
}
EUVIMED